hit counter

PGx Testing Found Actionable Genotypes in 30% of Veterans

MHD featured image for pharmacogenomic testing in veteran depression and antidepressant polypharmacy.

A 12-week randomized pilot trial in 60 Veterans with depression and psychiatric polypharmacy found that 30% had an actionable antidepressant gene-drug interaction, but immediate access to pharmacogenomic results did not clearly change prescribing or Patient Health Questionnaire-9 depression scores compared with delayed access.1 Research Highlights Actionable PGx results were common: 18 of 60 Veterans, or …

Read more

SSRI Pharmacogenomic Testing: CYP2D6, CYP2C19, Remission

MHD featured image for SSRI Pharmacogenomic Testing: CYP2D6, CYP2C19, Remission.

A 2026 methylome-wide association study by Shen et al. found 48 CpG methylation sites tied to the quadratic CYP2C19 metabolizer-status term in 18,396 Generation Scotland participants, with 19 sites showing non-linear patterns and targeted replication in 1,238 older adults.1 That supports CYP2C19 as real biology beneath SSRI pharmacogenomics, but it does not prove universal antidepressant …

Read more

Antidepressant Use in Pakistan (2026): SSRI Prescribing Patterns and Patient-Reported Side Effects

Photoreal illustration of a pharmacist counseling patient on antidepressant medication, conveying global pharmacovigilance.

Most antidepressant pharmacovigilance data come from high-income countries, leaving prescribing patterns and adverse-effect profiles in low- and middle-income countries underdocumented. A 2026 cross-sectional study by Riaz and colleagues describes antidepressant use in Pakistan, with patient-reported adverse effects mapped against prescription patterns.1 Research Highlights Antidepressant use in low- and middle-income countries (LMICs) has grown substantially but …

Read more

SSRIs + DOACs: No Excess Bleeding vs. Other Antidepressants

Stylized illustration of an SSRI capsule alongside a DOAC tablet against a vascular network background, representing the bleeding-interaction question in primary care.

SSRIs raise bleeding risk on their own. DOACs (direct oral anticoagulants — apixaban, rivaroxaban, dabigatran, edoxaban) raise it more. The intuitive worry is that combining them stacks the two effects. A new BJGP Open analysis from Chau and colleagues argues the stacking is smaller than most popular framings claim, and that the real safety question …

Read more

Ketamine Increases Amygdala Volume in Treatment-Resistant Depression (TRD) (2024 MRI Study)

Depression is a complex mental health condition that significantly affects an individual’s emotional and physical well-being. Recent advances in neuroimaging have provided deeper insights into how major depressive disorder (MDD) alters brain structures, particularly the hippocampus and amygdala, and how treatments like ketamine can potentially reverse these changes. A new study using 3T and 7T …

Read more

Nortriptyline-Induced “Room Tilt Illusion”: A Rare Adverse Event of Antidepressants (2024 Case Report)

Room Tilt Illusion (RTI) presents a perplexing challenge to both patients and physicians, transforming the familiar into the surreal as surroundings appear rotated or flipped. This rare condition, often linked to neurological or vestibular disorders, has recently been observed as an adverse effect of the antidepressant nortriptyline, used in treatment-resistant depression. A case report highlights …

Read more